文献速递神经肿瘤

声动力治疗成人型弥漫性胶质瘤:过去、现在与未来

Sonodynamic therapy for adult-type diffuse gliomas: past, present, and future.
PubMed 文献 · J Neurooncol · 2024-07-23

本文系统综述了声动力治疗(SDT)在成人型弥漫性胶质瘤中的应用。SDT利用声敏剂经超声激活产生活性氧诱导肿瘤细胞死亡。临床前研究显示5-氨基乙酰丙酸(5-ALA)、荧光素、卟啉衍生物和纳米颗粒等声敏剂联合聚焦超声(FUS)可实现靶向治疗和血脑屏障(BBB)破坏;临床试验在安全性和有效性方面显示希望,但需进一步研究以充分了解潜在不良反应并优化治疗方案。

要点

  • SDT利用声敏剂经超声激活产生活性氧诱导肿瘤细胞死亡。
  • 临床前研究显示5-ALA、荧光素、卟啉衍生物和纳米颗粒等声敏剂联合FUS可实现靶向治疗和BBB破坏。
  • 临床试验在安全性和有效性方面显示希望,但需进一步研究以充分了解潜在不良反应并优化治疗方案。

核心结论

  • SDT是治疗侵袭性脑肿瘤的一个有希望的前沿方向,为改善患者结局带来希望。

研究设计与样本

  • 本文为系统综述,按照系统综述和Meta分析优先报告条目(PRISMA)指南进行。

主要发现

  • 临床前研究显示5-氨基乙酰丙酸(5-ALA)、荧光素、卟啉衍生物和纳米颗粒等多种声敏剂联合FUS可实现靶向肿瘤治疗和BBB破坏。
  • 临床试验在安全性和有效性方面显示希望,但需进一步研究以充分了解潜在不良反应并优化治疗方案。
  • 颅骨厚度影响FUS穿透以及BBB开放的动力学是SDT临床成功实施需仔细考虑的问题。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intra-axial brain tumors persist as significant clinical challenges. Aggressive surgical resection carries risk of morbidity, and the blood-brain barrier (BBB) prevents optimal pharmacological interventions. There is a clear clinical demand for innovative and less invasive therapeutic strategies for patients, especially those that can augment established treatment protocols. Focused ultrasound (FUS) has emerged as a promising approach to manage brain tumors. Sonodynamic therapy (SDT), a subset of FUS, utilizes sonosensitizers activated by ultrasound waves to generate reactive oxygen species (ROS) and induce tumor cell death. OBJECTIVE: This review explores the historical evolution and rationale behind SDT, focusing on its mechanisms of action and potential applications in brain tumor management. METHOD: A systematic review was conducted using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS: Preclinical studies have demonstrated the efficacy of various sonosensitizers, including 5-aminolevulinic acid (5-ALA), fluorescein, porphyrin derivatives, and nanoparticles, in conjunction with FUS for targeted tumor therapy and BBB disruption. Clinical trials have shown promising results in terms of safety and efficacy, although further research is needed to fully understand the potential adverse effects and optimize treatment protocols. Challenges such as skull thickness affecting FUS penetration, and the kinetics of BBB opening require careful consideration for the successful implementation of SDT in clinical practice. Future directions include comparative studies of different sonosensitizers, optimization of FUS parameters, and exploration of SDT's immunomodulatory effects. CONCLUSION: SDT represents a promising frontier in the treatment of aggressive brain tumors, offering hope for improved patient outcomes.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Scanlon SE, Shanahan RM, Bin-Alamer O, et al. Sonodynamic therapy for adult-type diffuse gliomas: past, present, and future. J Neurooncol. 2024. PMID: 39042302. doi:10.1007/s11060-024-04772-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。